
Free Daily Podcast Summary
by KAMI Think Tank
At KAMI Think Tank, we love cutting through the AI hype to showcase where the technology actually stands and how to use it meaningfully within the life sciences. Now, we're bringing that same clarity with our community to a brand new podcast: From Models to Medicine. Every week, we sit down with a real practitioner in the life sciences, whether they're working in the lab, leading innovation at a biotech, or building tools to better serve scientists. We discuss how they cut through the hype of AI and practically leverage the tool in their scientific workflows. Glad to have you here.
The most recent episodes — sign up to get AI-powered summaries of each one.
This week, we sit down with Jean-Baptiste Morlot of Deep Life, who makes the case that the drug discovery field has been asking the wrong thing of its AI models. Correlation-based machine learning can find patterns, but it can't tell you why a cell is sick or what it would take to make it healthy again. Jean-Baptiste walks us through how single-cell sequencing unlocked the data volume needed to train something far more ambitious: a causal world model of cellular biology that learns the underlying rules of disease rather than memorizing them.We get into how Deep Life's TwinCell platform works, why most virtual cell benchmarks are quietly inflated by popularity bias, and what it means to build an interpretable AI that a biologist can trust.
This week, we sit down with Katie Lennon, CSO of Exthymic, who makes a case most bench scientists aren't ready to hear: biology isn't just a discovery discipline anymore. It's engineering. Katie walks us through what it actually looks like to build biology, hardware, and software concurrently, why that requires a shared language across disciplines, and what gets lost when teams hand off instead of collaborate.We also get into the unglamorous side of AI in the lab. More data documentation, peer-checking metadata before an experiment is marked complete, and knowing exactly where LLMs quietly get things wrong. Katie also shares a surprisingly effective strategy for getting scientists over their fear of AI tools. Companies mentioned in the show: https://exthymic.com/https://oni.bio/https://www.potato.ai/https://ollie.ai/-------------------Sign up for KAMI Think Tank's Maven course here! Classes start in less than 10 days!!
In this episode of From Models to Medicine, we sit down with Mark Amouzgar, co-founder and CEO of March Health. Mark opens with a striking stat: general-purpose AI models are only about 60% accurate in women's health. Sounding confident isn't the same as being clinically safe, and in this episode he breaks down exactly why generic AI was never built for this.We get into how March Health built a gender-aware digital twin, what it takes to wrap a model in real clinical logic, and why the average endometriosis patient sees eight different doctors before getting an accurate diagnosis. It's a candid conversation about a problem that doesn't get nearly enough attention.-------------------------Sign up for KAMI Think Tank's Maven course here!
In this episode of From Models to Medicine, we sit down with Lavanya Anandan, Head of External Innovation, West Coast at CSL, whose path from bench scientist to Merck Group platform builder to UCSF Innovation Venture startup advisor gives her a rare view of where AI in drug discovery is delivering versus where it's mostly promise. She makes a sharp case that the companies winning in AI-bio aren't necessarily the ones with the best models, and the reason why might surprise you.We get into what big pharma wants from an AI partner, why women's health data scarcity is quietly producing some of the most rigorous AI in biology, and what an unexpected finding in mRNA research tells us about where this whole field might be heading. Articles mentioned in show: https://endpoints.news/can-ai-do-scientific-research-billions-chase-hopes-of-superintelligence/Maven course: https://maven.com/kamithinktank/ai-literacy-for-life-sciences-healthcare
We chat with Karl Moritz, CEO of Reliant AI, now part of Cohere, whose career took him from NLP research to McKinsey to building AI infrastructure for drug development. Karl reminds us that clinical trial success rates have been stuck years, and the golden age of AI-powered target discovery isn't fixing it.Karl lays out a sharp framework; own the science, rent the AI plumbing, and explains why building your own data ingestion pipeline is as misguided as writing your own operating system. He's also candid about what general-purpose LLMs are actually good for, where purpose-built enterprise tools earn their keep, and why the audit trail question will separate serious AI vendors from everyone else. If you're a pharma or biotech leader trying to make sense of the build vs. buy debate right now, this one is worth your time.
For this episode, we sit down with Banishree Saha, Global Biomarkers Lead at Takeda, who has worked in fields such as academic liver biology to translational biomarker work, over the course of her 20-year career. She walks us through what biomarkers really are, how flow cytometry went from single-color panels to capturing 40 proteins simultaneously, and why that explosion in data has made systems thinking the only way forward.Banishree talks about AI's strengths and weaknesses, and makes the case that the scientists most at risk from AI aren't the ones who know too much biology. But are the ones who don't know enough to catch when the model is wrong.
In this episode, we sit down with Chris Nelson, an mRNA scientist at nCode Bio whose career has taken him from building blood transfusion matching tests now used by the NHS, to cancer genomics at Personalis, to the frontier of mRNA sequence design. Chris breaks down why the untranslated regions of mRNA might actually change how we dose therapeutics, reduce side effects, and engineer cells inside the body entirely.Then we talk about why AI has conquered protein folding but keeps hitting a wall with mRNA. Chris walks us through the data problem, the cost problem, and the modeling choices nCode Bio is making that go against the grain of what most of the field is building. He's also candid about where the big model providers are letting biology down and which scrappy research groups he thinks are quietly building the tools that will actually matter.
In this episode of From Models to Medicine, we sit down with Sarah Daniels, an environmental health researcher, who makes the argument that the chemicals making us sick might also be our best clues for building better drugs. She traces that idea from a 1976 discovery about dioxins all the way to an FDA-approved psoriasis treatment in 2023 — and asks what AI could accelerate if the field finally got its data act together.Sarah brings up where AI in environmental health is genuinely stuck; siloed industry data, models built only for acute toxicity, and a chronic low-dose problem that no one has cracked. She also shares how she used APIs to build her own real-time funding tracker for microplastics research in under a month, and why the gap between what AI promises and what environmental health can actually feed it is one of the most under appreciated bottlenecks in the field right now.Links mentioned in this episode: Historic ARPA-H program funding announcement on Microplastics: https://arpa-h.gov/explore-funding/programs/stompSarah's two cents on the ARPA-H Microplastics program: https://engineeredresilience.substack.com/p/a-microplastics-prelude-for-engineeredAggregated trends in microplastics from the non-peer-reviewed literature (Trendspotter App):https://www.engineeredresilience.org/microplasticsStay up to date on latest releases from Sarah's work on Engineered Resilience by signing up for substack: https://engineeredresilience.substack.com/Report on unexpected health effects observed after LA fires showing how questions remain post-exposure to pollutants:https://www.latimes.com/environment/story/2025-12-17/la-fires-heart-attacks-strange-blood-test-results-spikedCan a Biologist Fix a Radio? - great piece on the necessity to understand biology at the systems-level: https://www.cell.com/cancer-cell/fulltext/S1535-6108(02)00133-2
At KAMI Think Tank, we love cutting through the AI hype to showcase where the technology actually stands and how to use it meaningfully within the life sciences. Now, we're bringing that same clarity with our community to a brand new podcast: From Models to Medicine. Every week, we sit down with a real practitioner in the life sciences, whether they're working in the lab, leading innovation at a biotech, or building tools to better serve scientists. We discuss how they cut through the hype of AI and practically leverage the tool in their scientific workflows. Glad to have you here.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from From Models to Medicine in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of From Models to Medicine as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by KAMI Think Tank.
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
From Models to Medicine publishes weekly. Our AI generates a summary within hours of each new episode.
Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.